MX2023014740A - Tratamiento de la obesidad y trastornos relacionados con la obesidad. - Google Patents

Tratamiento de la obesidad y trastornos relacionados con la obesidad.

Info

Publication number
MX2023014740A
MX2023014740A MX2023014740A MX2023014740A MX2023014740A MX 2023014740 A MX2023014740 A MX 2023014740A MX 2023014740 A MX2023014740 A MX 2023014740A MX 2023014740 A MX2023014740 A MX 2023014740A MX 2023014740 A MX2023014740 A MX 2023014740A
Authority
MX
Mexico
Prior art keywords
obesity
related disorders
peptide
treatment
gip
Prior art date
Application number
MX2023014740A
Other languages
English (en)
Spanish (es)
Inventor
Mette Marie Rosenkilde
Sparre-Ulrich Alexander Hovard
Original Assignee
Antag Therapeutics Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antag Therapeutics Aps filed Critical Antag Therapeutics Aps
Publication of MX2023014740A publication Critical patent/MX2023014740A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2235—Secretins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/645—Secretins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
MX2023014740A 2021-06-10 2022-06-10 Tratamiento de la obesidad y trastornos relacionados con la obesidad. MX2023014740A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21178712 2021-06-10
PCT/EP2022/065826 WO2022258805A1 (en) 2021-06-10 2022-06-10 Treatment of obesity and obesity-related disorders

Publications (1)

Publication Number Publication Date
MX2023014740A true MX2023014740A (es) 2024-03-13

Family

ID=76502668

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023014740A MX2023014740A (es) 2021-06-10 2022-06-10 Tratamiento de la obesidad y trastornos relacionados con la obesidad.

Country Status (11)

Country Link
US (1) US20240277813A1 (enExample)
EP (1) EP4351630A1 (enExample)
JP (1) JP2024521398A (enExample)
KR (1) KR20240021212A (enExample)
CN (1) CN117881415A (enExample)
AU (1) AU2022289247A1 (enExample)
BR (1) BR112023024968A2 (enExample)
CA (1) CA3221661A1 (enExample)
IL (1) IL309128A (enExample)
MX (1) MX2023014740A (enExample)
WO (1) WO2022258805A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI4408840T1 (sl) 2021-09-27 2025-12-31 Terns Pharmaceuticals, Inc. Benzimidazolne karboksilne kisline kot agonisti GLP-1R
US12024507B2 (en) 2021-10-25 2024-07-02 Terns Pharmaceuticals, Inc. Compounds as GLP-1R agonists
AU2023224854A1 (en) 2022-02-23 2024-10-03 Terns Pharmaceuticals, Inc. Compounds as glp-1r agonists
PE20252787A1 (es) 2023-04-07 2025-12-22 Terns Pharmaceuticals Inc Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica
KR20260118441A (ko) 2023-11-21 2026-07-30 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 헤테로시클릭 화합물, 이의 제조 방법 및 의약에서 이의 응용
KR20250095833A (ko) * 2023-12-19 2025-06-27 한미약품 주식회사 에페글레나타이드를 유효성분으로 포함하는 약학 조성물 및 이의 투여 요법
TW202600132A (zh) 2024-03-08 2026-01-01 美商安尼波那生物公司 用於治療肥胖症及提高減重之方法
WO2026046202A1 (zh) * 2024-08-26 2026-03-05 博瑞生物医药（苏州）股份有限公司 Glp-1/gip肽或含有其的药物组合物的用途
KR102966075B1 (ko) * 2024-11-19 2026-05-19 (주)케어젠 항비만 및 항당뇨 활성을 갖는 펩타이드 및 이의 용도

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2597649A1 (en) * 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Inc. Gip analog and hybrid polypeptides with selectable properties
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
US12187773B2 (en) * 2018-12-03 2025-01-07 Antag Therapeutics Aps Modified GIP peptide analogues
CN122520749A (zh) * 2019-12-03 2026-08-07 安泰博医药 优化的gip肽类似物

Also Published As

Publication number Publication date
EP4351630A1 (en) 2024-04-17
WO2022258805A1 (en) 2022-12-15
US20240277813A1 (en) 2024-08-22
KR20240021212A (ko) 2024-02-16
CN117881415A (zh) 2024-04-12
JP2024521398A (ja) 2024-05-31
AU2022289247A1 (en) 2023-12-21
IL309128A (en) 2024-02-01
BR112023024968A2 (pt) 2024-02-20
CA3221661A1 (en) 2022-12-15

Similar Documents

Publication Publication Date Title
BR112023024968A2 (pt) Tratamento da obesidade e distúrbios relacionados à obesidade
MX2023002906A (es) Agonistas duales glp-1/gip.
MY197569A (en) Gip/glp1 co-agonist compounds
PH12022553526A1 (en) Long acting glp-1/gip dual agonists
JO3575B1 (ar) مركبات مساعد مشترك من gip وglp-1
MX2022014368A (es) Compuesto de agonista doble para receptores de glp-1 y gip y aplicacion del mismo.
SA518391903B1 (ar) معاضد مستقبل جلوكاجون/الببتيد 1 المشابه للجلوكاجون/البولي ببتيد المحب للأنسولين المعتمد على الجلوكوز الثلاثي
MX2022009149A (es) Compuestos coagonistas de gip/glp1.
WO2010054326A3 (en) C-terminal fragments of glucagon-like peptide-1 (glp-1)
EP4272823A3 (en) Pharmaceutical composition for treating sarcopenia comprising glucagon-like peptide-1 receptor agonist
CL2025000088A1 (es) Agonista dual de glp-1/gip, método de preparación y uso del mismo
MX2026000195A (es) Triagonista de los receptores glp-1, gip y gcg y su uso
EP4450127A3 (en) Method of using a gip/glp1 co-agonist for diabetes
IL318291A (en) Glucagon-like peptide 1 receptor antibodies
EA202092891A1 (ru) Соединения-коагонисты gip/glp1
ECSP23019850A (es) Agonistas duales glp-1/gip
TH2101000319A (th) สารประกอบอะโกนิสท์ร่วม gip/glp1
NZ755618B2 (en) Gip and glp-1 co-agonist compounds